Best Genomics Companies in North Rhine Westphalia, Germany
The 30 best Genomics companies in North Rhine Westphalia, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Singleron.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in North Rhine Westphalia
| # | Company | Last round | Disclosed funding | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AgroProtect Provider of agricultural consultation, data protection, and newsletter marketing services | — | — | — | 2010 | Dieter Peschen Founder & CEO | — | — | — |
| 2 | Carpegen Developer of point-of-care diagnostics for the detection of pathogens | — | — | — | 2001 | Antje Roetger Co-Founder & CEO | — | 20 patents Patents concentrated in transport & manufacturing processes | — |
| 3 | CoGAP Provider of exercise and nutrition plans tailored to the individual's DNA | — | — | 7 | 2009 | Simon Keller Managing Director | Cart FunctionalityWooCommerceWordPress+26 | — | — |
| 4 | CreativeTherapeutics Developer of therapies for treating cancer | — | — | — | 2009 | Hans Joachim Zeiler Co-Founder & CEO | — | — | — |
| 5 | DNA XY Provider of DNA based paternity test | — | — | — | 2005 | Yildirim Bor CEO | — | 2 patents DNA sequencing methods and systems for biopolymer analysis | — |
| 6 | FAIMA Artificial Intelligence based medical assistance | — | — | — | 2018 | Zainetdinov Emil CEO | — | — | — |
| 7 | FASTGenomics Provider of AI-based cell analysis and data management | — | — | — | 2016 | Stephan Huthmacher CEO | — | — | — |
| 8 | Liqomics Provider of liquid biopsy cancer diagnostics using ctDNA | — | — | — | 2021 | Sven Borchmann Founder & Managing Director | WordPressMySQLPHP+17 | — | — |
Top 12 Genomics companies in North Rhine Westphalia
#1
Series B · Hagen, North Rhine Westphalia · founded 2018$84.5Mraised▾
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis. It offers a product portfolio that includes instruments, microfluidic devices, reagents, software analysis, and database solutions that facilitate high-throughput single-cell analysis. It also, offers single cell sequencing services.
- Nov 2021Series B—
- Dec 2020Series A$30M
- Nov 2020Series A$10M
- Sep 2020Series A$30M
#2
Acquired · Cologne, North Rhine Westphalia · founded 2001 · 39 employees$28.4Mraised▾
Provider of glyco-optimized human cell lines and gene therapy vectors using proprietary cell expression system. The company has ELEVECTA technology for AAV manufacturing, CAP Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Provides the CAP GT expression platform, a scalable production system for gene therapy vectors. Also offers cell line development and protein expression services.
- Jul 2021Series E—
- Apr 2019Series D—
- Jul 2015Series C$4.9M
- Oct 2012Series C$3.6M
#3
Funding Raised · Bergisch Gladbach, North Rhine Westphalia · founded 1989 · 585 employees$12.7Mraised▾
Develops tools and products for research and clinical application. The company offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation, cell culture, molecular analysis, clinical application, and imaging. They have expertise in immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis.
- Mar 2021Grant (prize money)$304.4K
- Jan 2021Grant (prize money)$821.7K
- Jan 2020Grant (prize money)$539.1K
- Jun 2019Grant (prize money)$283.1K
#4
Deadpooled · Cologne, North Rhine Westphalia · founded 2010 · 40 employees$18.5Mraised▾
Ayoxxa Biosystems developed a technology platform for multiplexed protein analysis. The company's proprietary platform includes Lunaris BioChip that is used to identify and quantify proteins, including markers for cancer, allergies, cardiovascular or infectious diseases. It can be useful in biomedical research, pharmacological screening, and preclinical diagnostics development. The company also offers disease-specific detection kits such as 6-Plex Cytokine Kits to analyze biomarkers that are important in inflammation and in immune regulation.
- Jan 2017Grant (prize money)$21.9K
- May 2015Grant (prize money)$681.5K
- Dec 2014Series B$2.9M
- Jun 2014Series B$12.3M
#5
Acquired · Cologne, North Rhine Westphalia · founded 2012 · 30 employees$5.7Mraised▾
Provider of pharmacogenomics tests for cancer. The company uses next-generation sequencing (NGS) for variant detection of two gene panels: NeoPlus, which uses FFPE and other solid tissue samples, and NEOLiquid for the detection of circulating cell-free DNA.
- Oct 2015Series D$5.7M
- Mar 2015Series D—
#6
Funding Raised · Witten, North Rhine Westphalia · founded 1993 · 41 employees$608.2Kraised▾
Bitop develops bio-stabilizers for stabilizing nucleic acid, protein and cells against a variety of stress factors such as high temperatures, temperature fluctuations. In addition, it also manufactures cosmetic active ingredient, and bioactive compounds.
- Jan 2018Grant (prize money)$608.2K
#7
Funding Raised · Bonn, North Rhine Westphalia · founded 2002$325.8Kraised▾
LIFE & BRAIN provides research and development for the biomedical and neuroscientific technology platform. The company offers translational research for omics data interpreting diagnostic and therapeutic procedures. The company offers services for sequencing analyses using PacBio Sequel Technology, DNA Amplikonsequenzierung, de novo sequencing of genomes, re-sequencing of genomes, and Iso-Seq RNA sequencing.
- Jan 2020Grant (prize money)—
- Jan 2016Grant (prize money)$325.8K
- Jan 2015Grant (prize money)—
- Nov 2013Grant (prize money)—
#8
Acquired · Cologne, North Rhine Westphalia · founded 2010 · 27 employees$109.8Kraised▾
Sividon Diagnostics is a management buyout from Siemens Healthcare Diagnostics in Cologne. The company's main focus is in companion molecular diagnostics for personalized treatment of breast cancer. Sividon's EndoPredict is a second-generation, multigene prognostic test kit for patients diagnosed with breast cancer, detects the likelihood of metastases and helps guide treatment with chemotherapy as well as extended anti-hormone therapy. In Jan 2014, Myriad Genetics GmbH and Sividon Diagnostics GmbH announced that they have entered into an exclusive co-marketing agreement, covering the sales and marketing of Sividon's EndoPredict test outside of the United States
- Dec 2015Grant (prize money)$54.6K
- Jul 2015Grant (prize money)$55.2K
- Sep 2011Series A—
#9
Seed · Cologne, North Rhine Westphalia—raised▾
Developer of a diagnostic device for the detection of pathogens. It offers a cartridge system that consists of DetechStamp and DetechChip for nucleic acid detection of infectious pathogens.
#10
Public · Bielefeld, North Rhine Westphalia · founded 2000 · 31 employees—raised▾
PlasmidFactory is a contract manufacturer of Plasmid DNA for research, preclinical, clinical and commercial manufacturing purposes. They offer different grades of plasmids for research & preclinical studies (4 different grades) and commercial manufacturing purposes. Their High-Quality Grade plasmid DNA can be used in the GMP production of recombinant viruses, antibodies, induced pluripotent stem cells (iPS) and RNA used for clinical studies. The company claims that it can produce high-purity DNA, whose quality markedly exceeds that of kit-based systems, due to their unique capillary gel electrophoresis (CGE) technology which allows determination and quantification of the proportion of the ccc (covalently closed circular) form, which is the most reliable active conformation. They also offer specialised plasmids such as Helper Packaging Plasmids (for Adeno Associated Virus production), reporter genes, minicircle DNA(with only the gene of interest and its regulating sequence motifs).
- Sep 2022PE—
#11
Series B · Duisburg, North Rhine Westphalia · founded 2016 · 47 employees—raised▾
Developer of cell-free molecular assays. The company has developed a proprietary technology that identifies pathogens via next-generation sequencing of cell-free nucleic acids in patients' plasma samples. It detects bacteria, fungi, viruses, and parasites.
- May 2022Series B—
- Mar 2020Series A—
- Dec 2017Seed—
#12
Deadpooled · Dusseldorf, North Rhine Westphalia · founded 2011—raised▾
Epivios develops epigenetics-based molecular diagnostic tests for cancer. Its proprietary epigenetic platform enables the comparison of samples with dissimilar genetic constitutions with great accuracy. First application is for the early diagnosis of bladder cancer and prostate cancer. Current status of the company is unknown.
- Jul 2012Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising